What Are Biotechs Good At?
Executive SummaryBiotech companies have seen themselves as proto-drug companies. But the real talents of many of them have little to do with becoming fully integrated discovery-based drug firms. They should be performing core-competency reviews to uncover their real distinctive talents, and then exploiting them--talents which may lie in dealmaking (e.g., only one of Chiron's three main products comes from its internal research), marketing (e.g., perhaps Genentech's best skill is differentiating its drugs from cheaper alternatives), clinical development, or even distribution (a la Axion).
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.